Lewicky, J.D.; Martel, A.L.; Fraleigh, N.L.; Picard, E.; Mousavifar, L.; Nakamura, A.; Diaz-Mitoma, F.; Roy, R.; Le, H.-T.
Exploiting the DNA Damaging Activity of Liposomal Low Dose Cytarabine for Cancer Immunotherapy. Pharmaceutics 2022, 14, 2710.
https://doi.org/10.3390/pharmaceutics14122710
AMA Style
Lewicky JD, Martel AL, Fraleigh NL, Picard E, Mousavifar L, Nakamura A, Diaz-Mitoma F, Roy R, Le H-T.
Exploiting the DNA Damaging Activity of Liposomal Low Dose Cytarabine for Cancer Immunotherapy. Pharmaceutics. 2022; 14(12):2710.
https://doi.org/10.3390/pharmaceutics14122710
Chicago/Turabian Style
Lewicky, Jordan D., Alexandrine L. Martel, Nya L. Fraleigh, Emilie Picard, Leila Mousavifar, Arnaldo Nakamura, Francisco Diaz-Mitoma, René Roy, and Hoang-Thanh Le.
2022. "Exploiting the DNA Damaging Activity of Liposomal Low Dose Cytarabine for Cancer Immunotherapy" Pharmaceutics 14, no. 12: 2710.
https://doi.org/10.3390/pharmaceutics14122710
APA Style
Lewicky, J. D., Martel, A. L., Fraleigh, N. L., Picard, E., Mousavifar, L., Nakamura, A., Diaz-Mitoma, F., Roy, R., & Le, H. -T.
(2022). Exploiting the DNA Damaging Activity of Liposomal Low Dose Cytarabine for Cancer Immunotherapy. Pharmaceutics, 14(12), 2710.
https://doi.org/10.3390/pharmaceutics14122710